CN Patent

CN110051631A — 使用含脂质体伊立替康的组合疗法治疗胰腺癌的方法

Assigned to Ipsen Biopharm Ltd · Expires 2019-07-26 · 7y expired

What this patent protects

本发明提供通过单独施用或与其它治疗剂组合施用脂质体伊立替康(MM‑398)来治疗患者的胰腺癌的方法。在一个实施方案中，所述脂质体伊立替康(MM‑398)是与5‑氟尿嘧啶和甲酰四氢叶酸共施用的。

USPTO Abstract

本发明提供通过单独施用或与其它治疗剂组合施用脂质体伊立替康(MM‑398)来治疗患者的胰腺癌的方法。在一个实施方案中，所述脂质体伊立替康(MM‑398)是与5‑氟尿嘧啶和甲酰四氢叶酸共施用的。

Drugs covered by this patent

Patent Metadata

Patent number
CN110051631A
Jurisdiction
CN
Classification
—
Expires
2019-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Biopharm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.